Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Cited by 438 Publications

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Nat Biotechnol, 2018, 36(1):95-102

PubMed: 29176614 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Genet, 2018, 50(8):1086-1092

PubMed: 30013182 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):202-216

PubMed: 29358035 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nat Med, 2016, 22(2):194-201

PubMed: 26779812 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )
Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 145(4):529-42

PubMed: 21565612 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2000

PubMed: 31900275 ( click the link to review the publication )

Cancer Lett, 2020, 469:78-88

PubMed: 31629931 ( click the link to review the publication )

Sci Transl Med, 2019, 11(492)

PubMed: 31092693 ( click the link to review the publication )

Cell Res, 2019, 29(3):233-247

PubMed: 30728452 ( click the link to review the publication )

Nat Microbiol, 2019, 4(11):1872-1884

PubMed: 30988430 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.026

PubMed: 31759821 ( click the link to review the publication )

Mol Cell, 2019, 73(4):845-856

PubMed: 30712989 ( click the link to review the publication )

Mol Cell, 2019, 76(3):473-484

PubMed: 31494034 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.09.024

PubMed: 31653568 ( click the link to review the publication )

Mol Cell, 2019, 73(5):885-899

PubMed: 30686591 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1286-1298

PubMed: 31473101 ( click the link to review the publication )

Mol Cell, 2019, 73(2):224-237

PubMed: 30554948 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.008

PubMed: 31676232 ( click the link to review the publication )

Mol Cell, 2019, 73(6):1267-1281

PubMed: 30704900 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4363

PubMed: 31554794 ( click the link to review the publication )

J Clin Invest, 2019, 129(3):1211-1228

PubMed: 30589644 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5654

PubMed: 31827085 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5296

PubMed: 31757951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2849

PubMed: 31253762 ( click the link to review the publication )

Nat Commun, 2019, 10(1):241

PubMed: 30651562 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):65

PubMed: 30622262 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5661

PubMed: 31827092 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5501

PubMed: 31796734 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz820

PubMed: 31566235 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6127-6140

PubMed: 31409614 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6206-6216

PubMed: 31409613 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(7):e9982

PubMed: 31273933 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2549

PubMed: 31852834 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Genes Dev, 2019, 33(5-6):333-347

PubMed: 30796017 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

EMBO Rep, 2019, 20(5)

PubMed: 30940648 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32670

PubMed: 31495919 ( click the link to review the publication )

Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )
Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

Oncogene, 2019, 38(2):180-193

PubMed: 30093630 ( click the link to review the publication )

J Med Chem, 2019, 62(11):5330-5357

PubMed: 31042381 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627329 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):165

PubMed: 31775874 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0242

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Transl Res, 2019, 10.1016/j.trsl.2019.10.003

PubMed: 31707040 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(11):2442-2455

PubMed: 31815045 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(3):608-618

PubMed: 30949414 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )
Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31795418 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(33):12459-12471

PubMed: 31248990 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Virology, 2019, 537:254-262

PubMed: 31539774 ( click the link to review the publication )

Prostate, 2019, 79(4):390-402

PubMed: 30520109 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):829

PubMed: 31438892 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 10.1007/s00432-019-03097-6

PubMed: 31786739 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2528

PubMed: 31512408 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )
J Gynecol Oncol, 2019, 30(2):e26

PubMed: 30740957 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223725

PubMed: 31596905 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.050

PubMed: 31753490 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Am J Vet Res, 2019, 80(7):663-669

PubMed: 31246122 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2722-2737

PubMed: 31105872 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Commun Biol, 2019, 2:335

PubMed: 31508509 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:14

PubMed: 30993195 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(17):9132-9143

PubMed: 31329989 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(2):162-174

PubMed: 29335528 ( click the link to review the publication )

Mol Cell, 2018, 71(1):11-24

PubMed: 29937341 ( click the link to review the publication )

Mol Cell, 2018, 72(4):636-649

PubMed: 30293785 ( click the link to review the publication )

Mol Cell, 2018, 71(6):897-910

PubMed: 30122534 ( click the link to review the publication )

Mol Cell, 2018, 72(1):127-139

PubMed: 30244837 ( click the link to review the publication )
Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4525-4542

PubMed: 30222135 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3982

PubMed: 30266942 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1849

PubMed: 29748565 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2016

PubMed: 29789535 ( click the link to review the publication )

Nat Commun, 2018, 9(1):144

PubMed: 29321523 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403

PubMed: 30257201 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.37818

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.38771

PubMed: 29985131 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )
Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

PLoS Pathog, 2018, 14(11):e1007394

PubMed: 30395643 ( click the link to review the publication )

Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Int J Nanomedicine, 2018, 13:8063-8074

PubMed: 30555227 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:719-728

PubMed: 29524880 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1285-1296

PubMed: 29479816 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2261-2269

PubMed: 29512738 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )
PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0207934

PubMed: 30543656 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Blood Cells Mol Dis, 2018, 71:23-28

PubMed: 29422232 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(99):37319-37332

PubMed: 30647872 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:12-24

PubMed: 29807321 ( click the link to review the publication )

Oncotarget, 2018, 9(98):37080-37096

PubMed: 30647846 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

RNA Biol, 2018, 15(11):1420-1432

PubMed: 30362859 ( click the link to review the publication )

Sci Transl Med, 2017, 9(375)

PubMed: 28148839 ( click the link to review the publication )

Circ Res, 2017, 120(12):1889-1902

PubMed: 28356339 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 67(3):374-386

PubMed: 28735897 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )
Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Mol Cell, 2017, 68(2):414-430

PubMed: 29053959 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(11):902-910

PubMed: 28991266 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

J Clin Invest, 2017, 127(8):3013-3027

PubMed: 28691929 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2392-2406

PubMed: 28481221 ( click the link to review the publication )

Nat Commun, 2017, 8(1):859

PubMed: 29038466 ( click the link to review the publication )

Nat Commun, 2017, 8:14632

PubMed: 28272405 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Genes Dev, 2017, 31(1):46-58

PubMed: 28115467 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(33):4682-4691

PubMed: 28394338 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):63

PubMed: 28482906 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12876

PubMed: 28993682 ( click the link to review the publication )

Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Cell Cycle, 2017, 16(11):1128-1135

PubMed: 28463527 ( click the link to review the publication )

Transl Oncol, 2017, 10(2):190-196

PubMed: 28182994 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(11):2705-2716

PubMed: 28394191 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )

Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )
Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94505-94518

PubMed: 29212245 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29963-29975

PubMed: 28415784 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31815-31829

PubMed: 28415632 ( click the link to review the publication )

Oncotarget, 2017, 8(25):40152-40168

PubMed: 27374179 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

J Clin Invest, 2016, 126(8):2903-18

PubMed: 27454287 ( click the link to review the publication )

Nat Commun, 2016, 7:13837

PubMed: 27958275 ( click the link to review the publication )

Nat Commun, 2016, 7:12425

PubMed: 27498558 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )

EMBO J, 2016, 35(14):1488-503

PubMed: 27225932 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(6):1219-1228

PubMed: 26880244 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Br J Cancer, 2016, 114(7):777-86

PubMed: 26964031 ( click the link to review the publication )
Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

Cell Cycle, 2016, 15(22):3105-3114

PubMed: 27686740 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

BMC Cancer, 2016, 16:550

PubMed: 27465688 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(5):1071-8

PubMed: 26833244 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )
Oncotarget, 2016, 7(9):9732-41

PubMed: 26799421 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2016, 19(1):16-23

PubMed: 26805733 ( click the link to review the publication )

Oncotarget, 2016, 7(22):32980-9

PubMed: 27145275 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75551-75560

PubMed: 27705909 ( click the link to review the publication )

Mol Cancer, 2015, 14:114

PubMed: 26041471 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11):2560-8

PubMed: 26351319 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2818-30

PubMed: 26438158 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(5):1236-46

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(11):1465-77

PubMed: 26217019 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(10):1389-97

PubMed: 26116172 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

J Transl Med, 2015, 13:225

PubMed: 26169874 ( click the link to review the publication )

J Transl Med, 2015, 13:233

PubMed: 26183824 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )
Cell Cycle, 2015, 14(20):3261-9

PubMed: 26317799 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:3047-54

PubMed: 26543375 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43679-97

PubMed: 26544897 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

DNA Repair (Amst), 2015, 35:106-15

PubMed: 26519824 ( click the link to review the publication )

DNA Repair (Amst), 2015, 26:23-9

PubMed: 25541391 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Sci Transl Med, 2014, 6(222):222ra18

PubMed: 24500406 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Nat Commun, 2014, 5:3946

PubMed: 24867710 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )
Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Cell Death Differ, 2014, 21(2):258-69

PubMed: 24121277 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

PLoS Genet, 2014, 10(10):e1004654

PubMed: 25275444 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Radiother Oncol, 2014, 113(3):345-51

PubMed: 25467050 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )
Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1708-16

PubMed: 24675890 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Oncol Lett, 2014, 8(3):1222-1228

PubMed: 25120693 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):347-54

PubMed: 23396353 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

PLoS Genet, 2013, 9(6):e1003531

PubMed: 23785295 ( click the link to review the publication )

Mol Oncol, 2013, 7(3):567-79

PubMed: 23415752 ( click the link to review the publication )
Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2013, 15(6):600-8

PubMed: 23730208 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )

DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

PLoS Genet, 2012, 8(3):e1002574

PubMed: 22412391 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )
Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	M2G0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV[0JIQ>		MXvJR\|UxRTVwN{C1JEDPxE1i	NXHxTVRsOTh3NUm2NVM>
KP6.3	NEfjO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MljZOEBl		MYTJR\|UxRTFyLkSyPEDPxE1i	Mn\2NVg2PTl4MUO=
KP7.7	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW[0JIQ>		NGPMXpNKSzVyPUW3JI5OKA>?	NVjDSWJlOTh3NUm2NVM>
KB2P3.4	M{TLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTxOEBl		MVvJR\|UxRTF{NDDNJC=>	NWjLOWRMOTh3NUm2NVM>
KB2P1.21	NUixeWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV[3T4VXPCCm		NYnke2tlUUN3ME24PVA4KG6PIB?=	NV\FTmE2OTh3NUm2NVM>
U373-MG	MnjMR5l1d3SxeHnjJGF{e2G7	NU\0XWJ3OSEQvF2g	M4\oPFI1KGh?		NXTySHR5UW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	NWS3SZdIOTh7NUS3NVI>
T98G	Moi2R5l1d3SxeHnjJGF{e2G7	MlHZNUDPxE1i	NIjOU3MzPCCq		NHrSV\|lKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	MkHXNVg6PTR5MUK=
U87-MG	NFy1XphEgXSxdH;4bYMhSXO\|YYm=	M{PIRVEh\|ryPIB?=	MlTnNlQhcA>?		NICzZZhKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	NHz0e3oyQDl3NEexNi=>
UVW	NHWyW3ZEgXSxdH;4bYMhSXO\|YYm=	MojyOVAxKG6P	NGToT3MzPCCq		NUnZN29oUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	NVTGWVBKOTh7NUS3NVI>
HeLa	MV7GeY5kfGmxbjDBd5NigQ>?	NUWxbZpRPTByIH7N	M{fjVFQhcA>?		NVjDTVRHS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu\|	MYSxPFk2PDdzMh?=
HeLa	NIfr[GpHfW6ldHnvckBCe3OjeR?=	NHTmWYcyKM7:TTC=	M3nQT\|I1KGh?		NHjzcWFGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW\|dB?=	MlX6NVg6PTR5MUK=
T98G	MnfjSpVv[3Srb36gRZN{[Xl?	MkixNUDPxE1i	NYfabnFUOjRiaB?=		NYHyT\|hnTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S=	MV[xPFk2PDdzMh?=
L3	MV\DfZRwfG:6aXOgRZN{[Xl?	NF\Xb3g2KM7:TTC=	NFK0cHI6PiCq	NVHC[oZZTE2VTx?=	MWLTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	NYfMOFlbOjBzMkS0OVk>
Granta-519	MnfJR5l1d3SxeHnjJGF{e2G7	MoXpOUDPxE1i	MkPBPVYhcA>?	MWXEUXNQ	MXjTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	NH;iXoszODF{NES1PS=>
BT	MoS0R5l1d3SxeHnjJGF{e2G7	Mk\pOUDPxE1i	NYHnNmczQTZiaB?=	M2m3VmROW09?	NHu3VlFUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	MlXTNlAyOjR2NUm=
UPN2	Ml3YR5l1d3SxeHnjJGF{e2G7	M3fldlUh\|ryPIB?=	NGPUOW06PiCq	M3;HSGROW09?	MW\TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	MkfYNlAyOjR2NUm=
HBL-2	NFPFeIlEgXSxdH;4bYMhSXO\|YYm=	NUW3cWxCPSEQvF2g	MVq5OkBp	NIPsTotFVVOR	NX\QcGd1W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	M3rOVVIxOTJ2NEW5
JVM-2	MlvsR5l1d3SxeHnjJGF{e2G7	M3\0PVUh\|ryPIB?=	Mn3NPVYhcA>?	NVTKVppYTE2VTx?=	M{\ZUXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	NVfLdHo2OjBzMkS0OVk>
Z138	NFjBWVhEgXSxdH;4bYMhSXO\|YYm=	Mn[4OUDPxE1i	MY[5OkBp	M3\UU2ROW09?	Mn7PV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	MmfnNlAyOjR2NUm=
RWPE	NILG[2tKdn[jc3n2[UBCe3OjeR?=	MkKzNlUh\|ryP	NEflTJQ1QCCq	MkS0SG1UVw>?	M1KxSXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44>	Mnj6NlE2PzV6NkW=
VCaP	MXjJcpZie2m4ZTDBd5NigQ>?	MUiyOUDPxE1?	MXy0PEBp	NHvrWnJFVVOR	M1XOXHNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44>	MWCyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells	M1H6bGN6fG:2b4jpZ{BCe3OjeR?=	MYKyMlUh\|ryP	NFLLbYMzOCCq		MnXZV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	MX:yN\|M2PTR6OR?=
Mouse ATM−/− ES Cells	M1TZc2N6fG:2b4jpZ{BCe3OjeR?=	MXGyMlUh\|ryP	NF7BSGIzOCCq		NEfIWoxUcWewaX\pZ4FvfGy7IHnubIljcXS\|IHPlcIwhe3W{dnn2ZYw>	MlPJNlM{PTV2OEm=
H1650	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[yNEDPxE1?	NXrlV4F1OTR2IHi=		Mk[xTWM2OD1zNT60O{DPxE1?	MmDCNlMzOzl6MEm=
H1650PTEN+	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfUWmg1OjBizszN	NHfvUGIyPDRiaB?=		M3f1fGlEPTB;NUCuPFMh\|ryP	NFvGVoczOzJ\|OUiwPS=>
PC-9	NWW3coRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfiVYgzOCEQvF2=	MX[xOFQhcA>?		NXrsXIpkUUN3ME21Mlg5KM7:TR?=	M4LIPFI{OjN7OEC5
PC-9PTEN−	M3PuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDidVUzOCEQvF2=	MkLrNVQ1KGh?		NH7rcpZKSzVyPU[uOVIh\|ryP	NFvJVoozOzJ\|OUiwPS=>
MDA-MB-231	M3foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEfWZ2o2KGSjeR?=		NHr1dJdKSzVyPU[uPUDPxE1?	NGXjPVkzOzd4MES5Oi=>
MDA-MB-468	NGHFVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWTyeVhnPSCmYYm=		MWjJR\|UxRTVwMDFOwG0>	M4DlO\|I{PzZyNEm2
BT20	NULiUm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX\zbYhlPSCmYYm=		MoDMTWM2OD15Lkeg{txO	MXGyN\|c3ODR7Nh?=
HCC1143	NV7L[opsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEXteow2KGSjeR?=		M2f1W2lEPTB;MUGuNUDPxE1?	NHLpTGEzOzd4MES5Oi=>
HCC1937	NXr5UGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH7vfVY2KGSjeR?=		MWrJR\|UxRTF{Lk[g{txO	MXqyN\|c3ODR7Nh?=
Hs578t	M33icWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGT4d242KGSjeR?=		MYXJR\|UxRTVwNjFOwG0>	NGGxO44zOzd4MES5Oi=>
Hs578t(si)	NYTE[Vc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjpWos2KGSjeR?=		MX7JR\|UxRTdwNTFOwG0>	NVHGcpdvOjN5NkC0PVY>
BT474	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFq1PVM2KGSjeR?=		MmrqTWM2OD1zOT64JO69VQ>?	MXWyN\|c3ODR7Nh?=
JIMT1	NGP5TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13GTlUh\GG7		NUnyOo5GUUN3ME23Mlch\|ryP	NV;rdFdsOjN5NkC0PVY>
SKBR3	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIjL[GI2KGSjeR?=		MWDJR\|UxRTFzLkGg{txO	M2LsVlI{PzZyNEm2
SUM159	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkPEOUBl[Xl?		NUfhbHRLUUN3ME20MlIh\|ryP	NF\XdGozOzd4MES5Oi=>
CAMA1	NGGwRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFe1S3E2KGSjeR?=		NHi3S45KSzVyPUG1Mlgh\|ryP	MkD5NlM4PjB2OU[=
MCF7	NWjud2diT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFLCdlA2KGSjeR?=		NX[xfXBnUUN3ME21Mlgh\|ryP	NEDFeXozOzd4MES5Oi=>
T47D	NH2w[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYK1JIRigQ>?		M2C4bWlEPTB;OT62JO69VQ>?	NELifWszOzd4MES5Oi=>
HCT116	M4TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XnUlExOCEQvF2=	M{THR\|Q5KGh?	NYTXUnEzTE2VTx?=	M4TyTGlEPTB;Mj61JO69VSB?	Mn3wNlQ2Pzd7NEG=
SW1116	Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfIOWtuOTByIN88US=>	NU\kOnRvPDhiaB?=	MXTEUXNQ	NEG0W5pKSzVyPUGwNEDPxE1?	M{nreVI1PTd5OUSx
HT29	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n6T\|ExOCEQvF2=	M3HES\|Q5KGh?	MXjEUXNQ	NYTafnU4UUN3ME2xOE44KM7:TR?=	M2H6dFI1PTd5OUSx
LoVo	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorMNVAxKM7:TR?=	MUe0PEBp	MVPEUXNQ	MnfiTWM2OD1zMz60JO69VQ>?	NHPZfmkzPDV5N{m0NS=>
HCT-15	NXnhU25mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYraUldIOTByIN88US=>	MXS0PEBp	MmexSG1UVw>?	M2jYVmlEPTB;MUCg{txO	MV[yOFU4Pzl2MR?=
SW48	NYnDbWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TRNFExOCEQvF2=	NVH1OI5yPDhiaB?=	MlPQSG1UVw>?	NFfCZ5RKSzVyPUmuOUDPxE1?	MlLqNlQ2Pzd7NEG=
C-1	NX[1NnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\qfXEyODBizszN	NH63PFA1QCCq	M2\xXmROW09?	NYq2bm54UUN3ME23MlYh\|ryP	M{\icFI1PTd5OUSx
RKO	M3LxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fSSlExOCEQvF2=	NGPtOVQ1QCCq	Mm\3SG1UVw>?	MmLXTWM2OD13Lkmg{txO	NVfYNoVmOjR3N{e5OFE>
HCT116	NEjDbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7wNVAxKM7:TR?=	MWG0PEBp	MkXrSG1UVw>?	NWLpfG92WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NVz1NZJTOjR3N{e5OFE>
SW1116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnW3NVAxKM7:TR?=	MVq0PEBp	NU\4Oo5HTE2VTx?=	NGHBNY5Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	M{X1cVI1PTd5OUSx
HT29	NInwcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUWxNFAh\|ryP	M1rpUFQ5KGh?	Ml[5SG1UVw>?	NYHic5RjWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NHXjZoczPDV5N{m0NS=>
LoVo	NUXpdY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TZclExOCEQvF2=	NFfFRW01QCCq	NELNe4JFVVOR	MXjQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	MmPjNlQ2Pzd7NEG=
SW48	NGjtVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknENVAxKM7:TR?=	M{THclQ5KGh?	NWfDTIdsTE2VTx?=	NVnMPIRpWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	NXSxWFBEOjR3N{e5OFE>
C-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnPWWIyODBizszN	MVW0PEBp	M4[xO2ROW09?	M3vCW3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	NFHKcW4zPDV5N{m0NS=>
RKO	NVv1dIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\3NVAxKM7:TR?=	MnmyOFghcA>?	NUjTN2NyTE2VTx?=	M3fOW3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	NV3aNplmOjR3N{e5OFE>
HCT116	M4fpT2Z2dmO2aX;uJGF{e2G7	NETPWmkyOCCwTR?=	NF31fWoyOiCq	MXLEUXNQ	NFnWdm9KdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	NUXyN3VDOjR3N{e5OFE>
HT29	M3j6eGZ2dmO2aX;uJGF{e2G7	Mk\4NVAhdk1?	MojtNVIhcA>?	MVHEUXNQ	MWHJcoNz\WG\|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu\|IHnu[JVk\WRiYomgV24uOzh?	M2D2fFI1PTd5OUSx
TE-6	MUHGeY5kfGmxbjDBd5NigQ>?	NVvP[GdMPSEQvF2g	NGP5VFcyOiCq	M2TNS2ROW09?	NVvzRW5XUW6mdXPld{BIOi:PIHHydoV{fA>?	MnXpNlQzOTlzNkS=
TE-6	NHq1OHVHfW6ldHnvckBCe3OjeR?=	Ml;XOUDPxE1i	M2TFW\|I1KGh?	MVvEUXNQ	MX\JcoNz\WG\|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq	M2nZOVI1OjF7MU[0
Hep3B	NIPYfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoGwOFAh\|ryPIB?=	NIrpRYo4OiCq	MlzlSG1UVw>?	NVPxWFJKW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?	MViyOVA4Ojd3Mh?=
Huh7	M1vrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfyOFAh\|ryPIB?=	NW\DXGNiPzJiaB?=	MlL3SG1UVw>?	MWHTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>	Mk\KNlUxPzJ5NUK=
Hep3B	MofvSpVv[3Srb36gRZN{[Xl?	MmfJOFAh\|ryPIB?=	NVXJPWNpOjRiaB?=	NFTtfY1FVVOR	NHLP[5RKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG=	MVyyOVA4Ojd3Mh?=
Huh7	M1fxXGZ2dmO2aX;uJGF{e2G7	MnLhOFAh\|ryPIB?=	NFfTOGgzPCCq	MoOySG1UVw>?	NH\q[m1KdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG=	MUiyOVA4Ojd3Mh?=
Hep3B	M4HBXGZ2dmO2aX;uJGF{e2G7	MYG0NEDPxE1i	NUfHVGVxOjRiaB?=	NU[1fYlMTE2VTx?=	NHq4PVFKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG=	MojUNlUxPzJ5NUK=
Huh7	M4Dyd2Z2dmO2aX;uJGF{e2G7	M4jFVFQxKM7:TTC=	M1qwcVI1KGh?	NI\ndYtFVVOR	M17ZXWlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?=	M2DoRlI2ODd{N{Wy
SGC-7901	NEi5cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnqXYw{OMLizszN	M3ToW\|Q5KGh?	MoftSG1UVw>?	M{LKUWJtd2OtIH;4ZYxqeGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>	NFqwTIMzPTd4N{C3Oi=>
COLO-800	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGr1WZdKSzVyPUCuOFQyPjRizszN	M{HIe3NCVkeHUh?=
EoL-1-	M2TuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnwSJRiUUN3ME2wMlU3PDR4IN88US=>	MVPTRW5ITVJ?
NCI-H209	M1zjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDpPI5EUUN3ME2wMlkyPTV4IN88US=>	MUHTRW5ITVJ?
ES1	NIntSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HlRmlEPTB;MT6xNVQxQCEQvF2=	MVzTRW5ITVJ?
NKM-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUS0WI5VUUN3ME2xMlI2OzR5IN88US=>	MlHwV2FPT0WU
NTERA-S-cl-D1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\RcmlEPTB;MT6zN\|M1OSEQvF2=	M2n2V3NCVkeHUh?=
MHH-ES-1	M1\xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPhTWM2OD1zLk[yNFY4KM7:TR?=	MV3TRW5ITVJ?
ES8	NWDK[GJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzYTWM2OD1zLkeyOFE1KM7:TR?=	NIDLfZNUSU6JRWK=
NCI-H720	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXTTWM2OD1{LkKwOlk6KM7:TR?=	M4ri[3NCVkeHUh?=
EW-3	NXP4eFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXW0c3lTUUN3ME2yMlI4PTN2IN88US=>	NV7RXpZCW0GQR1XS
D-566MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NImycnlKSzVyPUKuOFQ2PjhizszN	NInURlFUSU6JRWK=
697	NILyZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJwOESxO\|Mh\|ryP	MUnTRW5ITVJ?
ES5	Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJwOEixPFkh\|ryP	NX7HV3hjW0GQR1XS
COLO-684	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrKTWM2OD1\|LkWxOlk3KM7:TR?=	MWTTRW5ITVJ?
ML-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTNwNkCwOVgh\|ryP	NWS2c25bW0GQR1XS
MC-IXC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zrdmlEPTB;Mz62N\|M6OyEQvF2=	NEnrZlRUSU6JRWK=
DB	M{fXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTTTWM2OD1\|Lk[1OFQ5KM7:TR?=	NH;iZ2VUSU6JRWK=
HCC2218	M4PONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfTTWM2OD1\|LkezNVA{KM7:TR?=	NYLoUnl1W0GQR1XS
NCI-H510A	NV3zeGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVS3WJo6UUN3ME2zMlgzPzJ2IN88US=>	M1m3eHNCVkeHUh?=
NCI-H526	M{DzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHBXnRKSzVyPUOuPFY6PThizszN	M3H3SXNCVkeHUh?=
MV-4-11	M4i3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS0TWM2OD12LkGzN\|M1KM7:TR?=	MX3TRW5ITVJ?
PA-1	Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTRwMkWyPUDPxE1?	M4DKbnNCVkeHUh?=
EW-22	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle0TWM2OD12LkO1PFYh\|ryP	M3zNfHNCVkeHUh?=
KASUMI-1	NFXuZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfCbnV2UUN3ME20MlQxOTB7IN88US=>	MojyV2FPT0WU
LU-139	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[5WIJKSzVyPUSuO\|U5OjlizszN	M37JWXNCVkeHUh?=
SBC-1	M3jiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXiW\|ZKSzVyPUSuPFA6ODhizszN	NFfJVllUSU6JRWK=
H4	NF\ZUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfHbnJKSzVyPUSuPFk1PDNizszN	M1PpOHNCVkeHUh?=
EW-11	NXPad2RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfoTWM2OD13LkC4NFczKM7:TR?=	MoXNV2FPT0WU
NBsusSR	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1P3fWlEPTB;NT6xNlA2PSEQvF2=	M4DyOHNCVkeHUh?=
RPMI-8226	NHnOVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTVwMUWyOFQh\|ryP	Mne3V2FPT0WU
DEL	NFvCU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWG3N4luUUN3ME21MlIxODB4IN88US=>	NFPIcopUSU6JRWK=
ES4	NIjQdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTVwNUGzPFkh\|ryP	MoPDV2FPT0WU
GCT	M1TIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVf1ZVRoUUN3ME21MlU3QDV4IN88US=>	Mo\tV2FPT0WU
NCI-H1048	M2j6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXWwfXhDUUN3ME21Mlk4Ojd\|IN88US=>	MYLTRW5ITVJ?
NCI-SNU-1	NIDreGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEe1eGFKSzVyPU[uNFIzKM7:TR?=	Mn;RV2FPT0WU
ES7	NIjqVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW0TWM2OD14LkCzOVc4KM7:TR?=	M2DoeHNCVkeHUh?=
SW982	MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLLZmNKUUN3ME22MlA6OTN5IN88US=>	NV;GeGprW0GQR1XS
L-363	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDWbFlGUUN3ME22MlM{QTd2IN88US=>	MU\TRW5ITVJ?
HT-1080	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWmzZYtyUUN3ME22MlQ6Pjh\|IN88US=>	Ml7IV2FPT0WU
HAL-01	NXP5dWtQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[1PWlEPTB;Nj61NVA6KM7:TR?=	MnTFV2FPT0WU
NB14	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTZwNkSwN\|kh\|ryP	MUjTRW5ITVJ?
EW-13	NXy4cHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDjU4VKSzVyPU[uO\|c1OjRizszN	MnzMV2FPT0WU
NY	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnOT2NHUUN3ME22Mlk1PjB3IN88US=>	NGG0V4JUSU6JRWK=
NCI-SNU-5	Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfwTWM2OD15LkGwOFM{KM7:TR?=	M4\pPHNCVkeHUh?=
MS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTdwMUe0PVQh\|ryP	MlLlV2FPT0WU
EW-16	NGX1WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjrcGlnUUN3ME23MlMyQDZzIN88US=>	NITFN2ZUSU6JRWK=
LU-65	NE\L[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHufZlKSzVyPUeuOFg1OTdizszN	MYLTRW5ITVJ?
HGC-27	NYDob4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn2wTWM2OD15LkeyNVc{KM7:TR?=	NFPIfFNUSU6JRWK=
CTB-1	NFjCdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DkZ2lEPTB;Nz63OlE4PSEQvF2=	Mmj4V2FPT0WU
5637	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjxOlg4UUN3ME23MlkzQDZizszN	M3XhVnNCVkeHUh?=
U251	M4\Hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDiU5FKSzVyPUeuPVQxOTZizszN	NEnTe2RUSU6JRWK=
HOS	M1\VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRThwMkOwNFch\|ryP	MmjoV2FPT0WU
DOHH-2	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfvTWM2OD16LkKzOVgh\|ryP	NVW0dWVtW0GQR1XS
EW-1	NVOxW4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjXTWM2OD16LkOwNFg5KM7:TR?=	NYHIdVQ2W0GQR1XS
BV-173	NVj4VWZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRThwNUW1OEDPxE1?	MUXTRW5ITVJ?
8-MG-BA	NH;YV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPNTWM2OD16Lk[4PVg5KM7:TR?=	MWjTRW5ITVJ?
NB69	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PncmlEPTB;OD63NFkzOSEQvF2=	NVjiWJpmW0GQR1XS
NCI-H69	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPoTWM2OD17LkmwPVYyKM7:TR?=	NY\BR2dxW0GQR1XS
RS4-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHmNXJKSzVyPUGxMlIzODhizszN	MnLBV2FPT0WU
ONS-76	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mki3TWM2OD1zMT6yPVQ4KM7:TR?=	MnezV2FPT0WU
SF539	NIrYVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnFe4VxUUN3ME2xNU41QDh7IN88US=>	MkPyV2FPT0WU
HuO-3N1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHMTWM2OD1zMT61O\|k3KM7:TR?=	NU\1eolmW0GQR1XS
NCI-H1651	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13xfWlEPTB;MUKuN\|EyPSEQvF2=	NFy2fpBUSU6JRWK=
KARPAS-45	M1m5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF{LkO3OkDPxE1?	NGnoVHNUSU6JRWK=
SK-NEP-1	M37OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVT3[XdPUUN3ME2xNk41PjB7IN88US=>	NG\oU4hUSU6JRWK=
LAMA-84	NX3i[Zh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfvTWM2OD1zMz6xNFk2KM7:TR?=	NWf3[IpVW0GQR1XS
NCI-H1155	NYHYOI95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfHNFFiUUN3ME2xN{4zQDV4IN88US=>	NUTaWoVPW0GQR1XS
CTV-1	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF\|LkS0OUDPxE1?	M{iwcHNCVkeHUh?=
QIMR-WIL	NIH0Z\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF\|Lke4NVQh\|ryP	MYHTRW5ITVJ?
H9	NULp[FhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37XeGlEPTB;MUOuPFQ4PSEQvF2=	NYDvd\|VLW0GQR1XS
SK-MEL-1	NGrHV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEToOoVKSzVyPUGzMlk{PDdizszN	MVHTRW5ITVJ?
HD-MY-Z	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe5b3JIUUN3ME2xOE4xPjN5IN88US=>	MmC0V2FPT0WU
TI-73	NH\iTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF2LkKzOVYh\|ryP	NV;Ldo1sW0GQR1XS
JVM-3	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnq[4V2UUN3ME2xOU42PzF4IN88US=>	MYfTRW5ITVJ?
D-247MG	NH7MfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTF3LkW5N{DPxE1?	MkjhV2FPT0WU
VA-ES-BJ	M1r3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF72W5pKSzVyPUG1MlYxQTdizszN	MnL3V2FPT0WU
NOS-1	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXTfJhKSzVyPUG1MlY2OjJizszN	MXjTRW5ITVJ?
MOLT-4	NYfXRZJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF4Lke1NkDPxE1?	M{jXenNCVkeHUh?=
Mo-T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfkRmRKUUN3ME2xO{4xQDR7IN88US=>	Mn3iV2FPT0WU
NCI-H1770	NF;IZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3j1WGlEPTB;MUeuNVU1OyEQvF2=	MYnTRW5ITVJ?
COLO-320-HSR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTF5LkG4Nlch\|ryP	MmfhV2FPT0WU
TE-12	M3frS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzGSI1KSzVyPUG3MlcxPTRizszN	NH\TOo9USU6JRWK=
NCI-H82	NW\iOHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrkSW9LUUN3ME2xO{45PzJ6IN88US=>	NWfTOXcyW0GQR1XS
NEC8	NVXmfFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTF6LkGzNVYh\|ryP	NXjSem1NW0GQR1XS
HSC-3	NFTMPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HmbWlEPTB;MUiuO\|QyPCEQvF2=	Ml\OV2FPT0WU
NCI-H1092	M2m3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTETWM2OD1zOD63OVk2KM7:TR?=	M{PnfXNCVkeHUh?=
NCI-H292	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF7LkC0PFkh\|ryP	MWnTRW5ITVJ?
L-428	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz3TWM2OD1zOT61OVkh\|ryP	NUTXUHJmW0GQR1XS
LU-134-A	NWW1WHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3GeIRKSzVyPUG5MlU4OiEQvF2=	M{P3S3NCVkeHUh?=
GI-ME-N	M{jJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoT5TWM2OD1zOT61O\|Q4KM7:TR?=	NFLl[FRUSU6JRWK=
ALL-PO	NV3lNIZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzoTWM2OD1zOT61PVczKM7:TR?=	MknFV2FPT0WU
D-283MED	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrFb254UUN3ME2xPU46OTVizszN	NF\5eVFUSU6JRWK=
D-423MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF7Lkm5Olch\|ryP	MoXXV2FPT0WU
CAKI-1	NFvtXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jTdWlEPTB;MkCuNlIyQSEQvF2=	NHzOSpJUSU6JRWK=
ETK-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XTSmlEPTB;MkCuNlYyPSEQvF2=	NYnaWHZFW0GQR1XS
G-402	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7YfIN7UUN3ME2yNE42OzN2IN88US=>	NHjETnZUSU6JRWK=
HL-60	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\mXGlEPTB;MkGuNVYyOyEQvF2=	Mle1V2FPT0WU
A2058	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD1SpAzUUN3ME2yNU41PDd5IN88US=>	MUfTRW5ITVJ?
CHP-212	M3fCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoKwTWM2OD1{MT65NFUyKM7:TR?=	M3ThbXNCVkeHUh?=
KY821	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorMTWM2OD1{MT65O\|Uh\|ryP	MW\TRW5ITVJ?
TYK-nu	NVvYXJlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUCxZYV[UUN3ME2yNk4xPjVzIN88US=>	M4D1ZXNCVkeHUh?=
JVM-2	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXFTWM2OD1{Mj6yPVg{KM7:TR?=	MnfMV2FPT0WU
KU812	MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTJ{LkezNVIh\|ryP	Ml3oV2FPT0WU
MKN28	NGjicFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[zfWlEPTB;MkKuPVAyPSEQvF2=	MWDTRW5ITVJ?
ECC10	MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlK4TWM2OD1{Mz63OFEh\|ryP	NGjwN4ZUSU6JRWK=
BHT-101	NXvsb\|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHES2JKSzVyPUK0MlAxODhizszN	NWHwU28{W0GQR1XS
DU-4475	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJ2LkOzN\|ch\|ryP	MWnTRW5ITVJ?
769-P	M2fL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJ2Lki0OlYh\|ryP	MYfTRW5ITVJ?
HEC-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;GSWlEPTB;MkWuOFQ2KM7:TR?=	NEi5NXdUSU6JRWK=
MOLT-13	M3L2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm4dI41UUN3ME2yOU42OzNzIN88US=>	MWrTRW5ITVJ?
8505C	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zrWGlEPTB;Mk[uOFk4PyEQvF2=	NHftd2VUSU6JRWK=
GB-1	NV;HUlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJ4LkexO\|Yh\|ryP	M2\J[HNCVkeHUh?=
SF126	NH;5dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW[5flhZUUN3ME2yOk44PjR6IN88US=>	NInYT2RUSU6JRWK=
A4-Fuk	NFO0[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzVfHZKSzVyPUK3MlEzPzFizszN	Mmn5V2FPT0WU
OVCAR-8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHITWM2OD1{Nz6xOVM6KM7:TR?=	MVzTRW5ITVJ?
NCI-H1304	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HOTmlEPTB;MkeuOVQh\|ryP	NYTONXZlW0GQR1XS
GR-ST	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jRVmlEPTB;MkiuNFQ4KM7:TR?=	NVLMdWhGW0GQR1XS
G-401	M4fWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILNTnhKSzVyPUK4MlUxQTZizszN	M1LvfXNCVkeHUh?=
LXF-289	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnjRmxKUUN3ME2yPE42PjVzIN88US=>	MoTCV2FPT0WU
DBTRG-05MG	NFjSXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTRTWM2OD1{OD65NlA1KM7:TR?=	M4G5dHNCVkeHUh?=
YKG-1	NITjTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TFcmlEPTB;MkmuPFY5KM7:TR?=	NH3oWFZUSU6JRWK=
GAMG	NX3SSIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTJ7Lkm5N{DPxE1?	MU\TRW5ITVJ?
HCT-116	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnSTWM2OD1\|MD6wOVQ5KM7:TR?=	MkPOV2FPT0WU
S-117	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofqTWM2OD1\|MT6yNlU4KM7:TR?=	MoD4V2FPT0WU
NCI-H1693	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\JTWM2OD1\|Mz62OVQzKM7:TR?=	MnvBV2FPT0WU
A427	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN\|Lkm5O\|Yh\|ryP	MkPqV2FPT0WU
HT-29	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV33Zm1QUUN3ME2zOE43ODN{IN88US=>	NWqwbZlrW0GQR1XS
P12-ICHIKAWA	M4DYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV70WZRoUUN3ME2zOE44PDlzIN88US=>	NFPaVJJUSU6JRWK=
CAL-51	NXTUc4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWmxRVV6UUN3ME2zOU4xPzB7IN88US=>	MlXNV2FPT0WU
Ramos-2G6-4C10	NXnuVG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTN3LkK0NlUh\|ryP	NFL3UnBUSU6JRWK=
SCH	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXXOmE2UUN3ME2zOk41OTd2IN88US=>	MnrxV2FPT0WU
SK-MEL-24	NE[xZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTN4LkmwOFQh\|ryP	MYTTRW5ITVJ?
SW1573	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIewcpJKSzVyPUO4MlczOTZizszN	M3\aeXNCVkeHUh?=
BALL-1	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzYTWM2OD1\|OT6yNVI6KM7:TR?=	MWLTRW5ITVJ?
BE-13	NWDL[GhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTN7LkOyPUDPxE1?	M37ufXNCVkeHUh?=
GI-1	M13WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2CyXmlEPTB;M{muPFY1PyEQvF2=	NVzjSoNMW0GQR1XS
GOTO	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN7LkmxN\|kh\|ryP	MkjwV2FPT0WU
A673	NGn4UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVW1U2NyUUN3ME20NU4xOzR\|IN88US=>	MmD1V2FPT0WU
KG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzCVohmUUN3ME20N{4{QTRizszN	Mn\rV2FPT0WU
GP5d	NEXITmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfXTWM2OD12ND6wOlY3KM7:TR?=	MmPvV2FPT0WU
MFM-223	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jlOGlEPTB;NESuNVIzQCEQvF2=	MV3TRW5ITVJ?
OAW-42	NYfaR2ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\5TWM2OD12ND6yOlQ{KM7:TR?=	MnrHV2FPT0WU
C8166	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTR3LkC4NlIh\|ryP	M4\0dXNCVkeHUh?=
LU-99A	NVfJ[mg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGToW21KSzVyPUS2MlE{OjJizszN	MkDWV2FPT0WU
NCI-H23	NXft[ZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXtTWM2OD12Nj6xO\|g2KM7:TR?=	NWDkU2xmW0GQR1XS
HO-1-N-1	M{fE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{njWGlEPTB;NEeuNFk6QCEQvF2=	MXHTRW5ITVJ?
A3-KAW	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TBVWlEPTB;NEeuNVAxPyEQvF2=	NVTHPIJ5W0GQR1XS
CGTH-W-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPVNHBKSzVyPUS3MlUxPjlizszN	MUjTRW5ITVJ?
DJM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTR5LkW0NVMh\|ryP	NEjRW4xUSU6JRWK=
A101D	NGTEZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV[wVFdjUUN3ME20O{43OzV5IN88US=>	M1jk[XNCVkeHUh?=
BB30-HNC	NILBZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHSeYhKSzVyPUS4MlMxPzJizszN	M1;pfnNCVkeHUh?=
T98G	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPDW4NKSzVyPUS4MlQ3OzNizszN	MVHTRW5ITVJ?
NCI-H1573	M4L3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXraRlc3UUN3ME20PU41PDZ{IN88US=>	MoDEV2FPT0WU
MEG-01	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELtUIJKSzVyPUS5Mlc1OTFizszN	NV7ZXG1mW0GQR1XS
WM-115	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;1S3lIUUN3ME20PU46OjJ{IN88US=>	M3;vT3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	- Collapse Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

- Collapse

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04024254	Not yet recruiting	Drug: Folic Acid Tablet	Ovarian Cancer\|Breast Cancer\|Folic Acid Deficiency	Rush University Medical Center	August 2019	Phase 2\|Phase 3
NCT04005690	Recruiting	Drug: Cobimetinib\|Drug: Olaparib	Resectable Pancreatic Ductal Adenocarcinoma\|Stage 0 Pancreatic Cancer AJCC v8\|Stage I Pancreatic Cancer AJCC v8\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	August 1 2019	Phase 2
NCT03786796	Recruiting	Drug: Olaparib	Renal Cell Carcinoma\|Metastatic Renal Cell Carcinoma\|Kidney Cancer\|Renal Carcinoma\|Kidney Cancer Metastatic	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	June 3 2019	Phase 2
NCT03745950	Not yet recruiting	Drug: Olaparib Oral Capsule\|Drug: Placebo oral capsule	Endometrial Carcinoma	ARCAGY/ GINECO GROUP	February 1 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 438 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281, Ku-0059436)

Cited by 438 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Olaparib (AZD2281, Ku-0059436) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)